ToxGenSolutions
Toxicity tests, preclinical diagnostics and preventive therapeutics for three high impact pathologies triggered by environmental factors
Currently we are working on a new website design: https://toxgen.solutions
Visit us there!
Visit us there!
(Epi-)genetic approaches addressing molecular initiation events and key events of adverse outcome pathways driving pathologies like neurodegeneration, cancer and immune-dysfunction
Breaking News and Latest Headlines
- ToxGenSolutions is moving from early diagnostics of Alzheimer’s Disease to drug target identification and drug development.
- 2. ToxGenSolutions BV identifies a 9 miRNA peripheral profile to identify individuals at risk for late-onset Alzheimer’s Disease years in advance
- 1. ToxGenSolutions BV identified a 9 miR periferal profile that can identify individuals at risk for acquiring late-onset Alzheimer’s Disease years in advance
- LATEST NEWSLETTER OF THE INTERREG. PROJECT ”HERINNERINGEN” (”MEMORIES”)
- HUMAN SAMPLES SUPPORT THE RELEVANCE OF 20 ‘ENVIRONMENTAL’ miR’s
- FIRST EVIDENCE FOR AN ‘ENVIRONMENTAL’ miR PROFILE FOR SPORADIC ALZHEIMER’S DISEASE
- TOXGENSOLUTIONS RECOGNIZED AS VALUABLE PARTNER FOR INNOVATION AND ENTREPRENEURSHIP IN CHINA
- DECEMBER 16TH, 2019: 2ND SYMPOSIUM OF THE INTERREG PROJECT ‘MEMORIES’.
- TOXGENSOLUTIONS REPRESENTED THE INTERREG. PROJECT ”MEMORIES” DURING THE 29th ALZHEIMER’S EUROPE CONGRESS IN THE HAGUE.
-
ToxGenSolutions is moving from early diagnostics of Alzheimer’s Disease to drug target identification and drug development.
ToxGenSolutions is currently validating at diagnostic tool allowing for preclinical diagnostics of Alzheimer’s Disease with focus on differences between men and women.
Yet, we are expanding our activities by moving towards drug target identification and drug development aiming at stopping disease development as early as possible. Our genetic and epi-genetic networks allowed the identification of 3 potential drug targets. Currently potential drugs are being identified using computational tools. Selected drug candidates are subjected to in vitro HTS for assessing toxicity (step 1) as well as for assessing efficacy (step 2) using brain spheroids composed of neurons, glia cells and astrocytes. The BBB will also be included both in toxicity and efficacy assessment.
-
2. ToxGenSolutions BV identifies a 9 miRNA peripheral profile to identify individuals at risk for late-onset Alzheimer’s Disease years in advance
14.02.2023
As part of an effort to drive the development of cutting-edge biomarkers and explore novel diagnostic technologies, ToxGenSolutions BV has identified a peripheral profile of 9 microRNAs (miRNAs) to identify individuals at risk for late-onset Alzheimer’s Disease (AD) years in advance.
The goal of the program is to diagnose late-onset Alzheimer’s Disease:
- Faster by turning the months/years it takes for the current diagnostic approach into hours.
- Cheaper by eliminating the dependence on expensive imaging.
- More accurate in the prodromal phase of the disease. Currently, nearly 50% of individuals diagnosed with mild cognitive impairment (MCI) do not develop dementia.
- Less invasive and more patient-friendly by replacing CSF sampling with a standard blood draw.
It is our pleasure to announce that the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation (ADDF) will support ToxGenSolutions BV in this endeavour.
-
1. ToxGenSolutions BV identified a 9 miR periferal profile that can identify individuals at risk for acquiring late-onset Alzheimer’s Disease years in advance
28.10.2022
This proposal addresses the objective to drive the development of cutting-edge biomarkers and to explore novel diagnostic technologies.
The ultimate goal of our program is to make diagnosis of late-onset Alzheimer’s Disease (AD):
- faster by turning the months/years it takes for the current diagnostic approach into hours,
- cheaper by eliminating expensive scans (e.g., €2,000-€2,500/$3,000-$4,500 for PET scans),
- more accurate in the prodromal phase of the disease with currently 50% of individuals diagnosed with mild cognitive impairment (MCI) not developing dementia,
- less invasive by replacing CSF sampling with blood sampling (urine as an option).
Our work-hypothesis: Individuals at risk for progressing into AD must be identified early if future drugs (once available) are to have any effect on the quality of life. Thus, novel biomarkers should reflect processes that are in transition from normal physiology into AD related pathology before neurons start to die off and the brain volume shrinks.
Next step: The prognostic profile is currently being validated with the support from the EU EuroStars programme. The product will be a biosensor device providing results within 3 hours after the blood/urine sample was taken, with a 90% accuracy according to the data that emerged from a pilot study.
Outreach: ToxGenSolutions is reaching out to investors and companies active in the field of diagnostics and drug development with the purpose of setting up commercial collaborations.
-
LATEST NEWSLETTER OF THE INTERREG. PROJECT ”HERINNERINGEN” (”MEMORIES”)
Unfortunately, the Covid-19 pandemic has also impacted the progress being made by the #Interreg. Vlaanderen-Nederland project ”Herinneringen” (”Memories”). But, progress was made, and the prolongation with 6 months that was approved by #Interreg. will allow us to reach the goal. Read more about it in our latest newsletter.
-
HUMAN SAMPLES SUPPORT THE RELEVANCE OF 20 ‘ENVIRONMENTAL’ miR’s
Differentially expression analysis of human iPSCs derived neurons, and human brain slices, blood samples and cerebrospinal fluid from Alzheimer’s patients and control individuals has identified 20 potential biomarkers affecting processes and pathways that are relevant for Alzheimer’s disease progression.
For further information: https://herinneringen.eu/nl
-
FIRST EVIDENCE FOR AN ‘ENVIRONMENTAL’ miR PROFILE FOR SPORADIC ALZHEIMER’S DISEASE
After several months of lockdown, the Interreg. VL-NL supported project Herinneringen (Memories) was able to finalize the genetic analyses of the human iPSC derived neurons exposed to selected environmental risk factors and biopsies from Alzheimer’s patients and control individuals. Differential gene and pathway analysis revealed processes in patient derived iPSC and biopsies that were not seen in material from control individuals. Currently, 9 miR’s have caught our attention for further evaluation.
-
TOXGENSOLUTIONS RECOGNIZED AS VALUABLE PARTNER FOR INNOVATION AND ENTREPRENEURSHIP IN CHINA
-
DECEMBER 16TH, 2019: 2ND SYMPOSIUM OF THE INTERREG PROJECT ‘MEMORIES’.
The symposium took place in the very attractive location called Promotie Zaal at the KULeuven which breaths the ancient atmosphere of scientific lectures and thesis defenses over the past centuries.
During the scientific morning session researchers from the universities of Hasselt, Ghent, Brussels, Leuven and Antwerp provided an update on the current status of Alzheimer’s research in general and within our project. Our understanding of the mechanisms driving the development of Alzheimer’s disease is growing and may result in the discovery of diagnostics and therapeutics.
The afternoon session targeted the general public. Kim Plasman (Stichting Alzheimer Onderzoek Belgium) Prof. Frans Verhey (University Maastricht), Prof. Sebastiaan Engelborghs (Universiteit of Antwerp) and Prof. Jos Kleinjans (University Maastricht) gave their more general overview about the current knowledge of this neurodegenerative disease. The Dutch journalist and publicist Hugo Borst closed the Symposium with sharing his personal experiences with his mother, who suffered from Alzheimer’s, reading touching passages from his latest book “Ach moedertje”.
-
TOXGENSOLUTIONS REPRESENTED THE INTERREG. PROJECT ”MEMORIES” DURING THE 29th ALZHEIMER’S EUROPE CONGRESS IN THE HAGUE.
ToxGenSolutions presented a poster showing the approach adopted by the Interreg. project to develop a test for diagnosis of Alzheimer’s disease before it strikes (29th AEC_poster_PO.20.11). The congress was characterized by a high representation of technologies and technological developments that focusses on monitoring the patients. Presentations on scientific progress were limited, and focussing on the clinical phase of disease: ”Looking at Alzheimer’s through the peephole of dementia” as one of the speakers stated. Beside our poster, there was little, if at all, focus on the impact of environmental factors on induction and development of Alzheimer’s.
Human Safety and Health based on Human Relevant (Epi-)Genetics
A VIRTUAL GENERIC (EPI-)GENETICS-BASED PLATFORM THAT PROVIDES ANSWERS TO YOUR QUESTIONS ABOUT SAFETY AND EFFICACY OF YOUR PRODUCTS.
NEXT-GENERATION TOOLS
-
A systems-based technology platform for profiling the positive as well as negative impact of compounds and product on (patho-)physiological responses and human health at realistic concentrations and under relevant exposure regimes.
-
Our toolbox contains a breadth of technologies, systems, and pathways and common nodes of toxicity and pathology.
-
The available toolbox is useful for the identification of new opportunities for product development in the chemical, cosmetic, food, diagnostics and pharmaceutical sector.
-
The toolbox is flexible, faster than traditional methods, more economical and more relevant for human safety and health.
FRONT-EDGE TECHNOLOGIES
-
ToxGenSolutions products are proprietary mechanism-based (epi-)genetic signatures for identification and classification of new leads and toxicants during screening, product development and safety assessment.
-
ToxGenSolutions provides a front-edge patchwork of test methods required for modern testing and assessment of compounds and products through tight collaboration with front-runners in the area of human tissue development.
-
ToxGenSolutions exploits the (epi-)genetic data to develop diagnostics for high impact pathologies (e.g. neurodegenerative diseases, cancer, immuno-dysfunction) in a preclinical stage.
FOCUS ON YOUR NEEDS
-
ToxGenSolutions develops testing and assessment strategies for, and with, you to assure optimal coverage of your needs.
-
ToxGenSolutions develops strategies considering the nature of the test substance, the intended application, likely exposure routes, product development status and legislation.
Engaging front-runners in a multidisciplinary approach for a safer future
Future perspectives
Diagnostic devices for high impact pathologies, triggered by environmental risk factors and life style, incorporating artificial intelligence based on big.
Advanced in vitro platform for personalized cancer medicine and treatment using intestinal human tissue, representing a very fast method to test individual responses to a drug and to determine the safe but effective dosage.
New therapeutic targets allowing for treatment of neurodegenerative diseases in a preclinical stage.
The impact of inflammatory signals on cell-cell communication in the brain using state-of-the-art in vitro methods.
An ontology-driven and artificial intelligence-based strategy, linked with a battery of in vitro assays and in silico tools for hazard prediction, combined with tailored exposure assessment for human risk assessment.
INFORMATION
Do you have any questions to our services then you are welcome to contact us today. Call us or send an email and then we will reply as soon as possible.
CONTACT ADDRESS
ToxGenSolutions B.V.
Oxfordlaan 70
6229 EV Maastricht, The Netherlands
CONTACT US
Phone: +45 3153 8020
Email: erwin.roggen@toxgensolutions.eu
Facebook: Click here
Twitter: Click here